
Biocon Limited has informed the Exchange about press release dated 01-Apr-2022 titled 'Biocon Biologics��� Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion'.
Filed with NSE ·

Biocon Limited has informed the Exchange about press release dated 01-Apr-2022 titled 'Biocon Biologics��� Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion'.
6ix hasn’t read this filing yet.
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon